var data={"title":"Tapentadol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tapentadol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/376030?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tapentadol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tapentadol: Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50847616\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opioid Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada, in collaboration with manufacturers, will update the Canadian labelling of all prescription opioid products to include the following:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation for a daily opioid threshold dose for the management of chronic noncancer, nonpalliative pain (which aims to reduce risks of adverse events and overdoses associated with higher doses of opioids);</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation to limit the quantity of opioids prescribed for acute pain (which aims to reduce the duration of use and associated risks of developing dependence and substance use disorder); and</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Clarification of warnings, including those for special populations such as pregnant women and patients with a history of dependence or substance use disorder.</p></li></ul>\n        <p style=\"text-indent:0em;\">Health Canada has prioritized product tables for updating based on risk. The labelling updates for all prescription opioids are expected to be completed in January 2019.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65362a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13210109\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Addiction, abuse, and misuse:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing tapentadol and monitor all patients regularly for the development of these behaviors or conditions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life-threatening respiratory depression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious, life-threatening, or fatal respiratory depression may occur with use of tapentadol. Monitor for respiratory depression, especially during initiation of tapentadol or following a dose increase. Instruct patients to swallow tapentadol ER tablets whole; crushing, chewing, or dissolving tapentadol can cause rapid release and absorption of a potentially fatal dose of tapentadol.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Accidental ingestion:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Accidental ingestion of even one dose of tapentadol, especially by children, can result in a fatal overdose of tapentadol.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neonatal opioid withdrawal syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prolonged use of tapentadol during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Interaction with alcohol (extended-release):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Instruct patients not to consume alcoholic beverages or use prescription or nonprescription products that contain alcohol while taking tapentadol ER. The coingestion of alcohol with tapentadol ER may result in increased plasma tapentadol levels and a potentially fatal overdose of tapentadol.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with benzodiazepines or other CNS depressants:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of tapentadol  and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878273\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nucynta;</li>\n      <li>Nucynta ER</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12785498\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Nucynta ER;</li>\n      <li>Nucynta IR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7083927\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Opioid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878389\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dose and dosage intervals should be individualized according to pain severity with respect to patient&rsquo;s previous experience with similar opioid analgesics. In patients receiving tapentadol ER, immediate-release opioid or nonopioid medication may be used for rescue relief of breakthrough pain and during dosage adjustments. Opioid tolerance is defined as: Patients already taking at least morphine 60 mg orally daily, oxymorphone 25 mg orally daily, transdermal fentanyl 25 mcg per hour, oxycodone 30 mg orally daily, hydromorphone 8 mg orally daily, hydrocodone 60 mg orally daily or an equivalent dose of another opioid for at least 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuropathic pain associated with diabetic peripheral neuropathy:</b> Oral: Extended release:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Opioid naive (use as the first opioid analgesic or use in patients who are <b>not</b> opioid tolerant): Initial: 50 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion from other opioids to tapentadol ER: Initial: 50 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion from tapentadol immediate release to ER: Convert using same total daily dose but divide into 2 equal doses and administer every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion from methadone to tapentadol ER: Close monitoring is required when converting methadone to another opioid. Ratio between methadone and other opioid agonists varies widely according to previous dose exposure. Methadone has a long half-life and can accumulate in the plasma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dosage titration:</b> Titrate in increments of 50 mg no more frequently than twice daily every 3 days to effective dose (therapeutic range: 100 to 250 mg every 12 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Pain management:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release tablets and solution:</i> Day 1: 50 to 100 mg (2.5 to 5 mL) every 4 to 6 hours as needed; may administer a second dose &ge;1 hour after the initial dose (maximum dose on first day: 700 mg/day); Day 2 and subsequent dosing: 50 to 100 mg (2.5 to 5 mL) every 4 to 6 hours as needed (maximum: 600 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conversion from tapentadol immediate release to ER: Convert using same total daily dose but divide into 2 equal doses and administer every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended-release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Opioid naive (use as the first opioid analgesic or use in patients who are <b>not</b> opioid tolerant): Initial: 50 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conversion from other opioids to tapentadol ER: Initial: 50 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conversion from tapentadol immediate release to ER: Convert using same total daily dose but divide into 2 equal doses and administer every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conversion from methadone to extended release tapentadol: Close monitoring is required when converting methadone to another opioid. Ratio between methadone and other opioid agonists varies widely according to previous dose exposure. Methadone has a long half-life and can accumulate in the plasma.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Dosage titration: </b>Titrate in increments of 50 mg no more frequently than twice daily every 3 days to effective dose (therapeutic range: 100 to 250 mg every 12 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Discontinuation of therapy:</b> Decrease previous daily dose by 25% to 50% each day every 2 to 4 days; monitor carefully for signs/symptoms of withdrawal. If patient displays withdrawal symptoms, increase dose to previous level and then reduce dose more slowly by increasing interval between dose reductions, decreasing amount of daily dose reduction, or both.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878390\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Initiate therapy at low end of dosing range and use caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878324\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: Use not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878325\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moderate impairment (Child-Pugh class B):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Initial: 50 mg every 8 hours or longer (maximum: 150 mg/24 hours). Further treatment for maintenance of analgesia may be achieved by either shortening or lengthening the dosing interval.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Initial: 50 mg every 24 hours or longer; maximum: 100 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment (Child-Pugh class C): Use not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878394\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nucynta: 50 mg, 75 mg [contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nucynta: 100 mg [contains fd&amp;c yellow #6 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 12 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nucynta ER: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nucynta ER: 100 mg, 150 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nucynta ER: 200 mg, 250 mg [scored; contains fd&amp;c blue #2 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7083931\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12809985\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nucynta IR: 50 mg, 75 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Controlled Release, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nucynta ER: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878271\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874994\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Nucynta: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022304s016lbl.pdf#page=32&amp;token=9EUFgxrcbCws0zSwH4+G+FjHw/xnncZMaYuYxAGOB5wTYTWd6wG2vDhVL6MKHtHnC13MyPkuMsal7QiCaZtEeUDji+90OpoD8PiXJQWOTMxT3RiqybbCbb6AvDwVcVaC&amp;TOPIC_ID=9511\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022304s016lbl.pdf#page=32</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Nucynta ER: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/200533s014lbl.pdf#page=32&amp;token=2Uno9LAjlXMroyBYKOoyZk9KdQWiAEuPkCgluAifWbhgZL6V+ppW8HdvWqZbtZQKuhu13oWcFs4Qai/KDGOx0qhHy19Z9JyIJjm88UGR8RzSb0FG3srnW5c3XiBTJpDd&amp;TOPIC_ID=9511\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/200533s014lbl.pdf#page=32</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878392\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ER tablets: Swallow whole; do <b>not</b> split, crush, break, chew, cut, or dissolve. Administer 1 tablet at a time with sufficient water to ensure complete swallowing immediately after placing in mouth.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Always use the enclosed calibrated oral syringe to ensure the dose is measured and administered accurately.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7083929\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuropathic pain associated with diabetic peripheral neuropathy:</b> Extended-release: Management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. <b>Note:</b> Tapentadol ER is generally not recommended as first or second line therapy due to a high risk for addiction and safety concerns compared to modest pain reduction (Pop-Busui 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release: Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatments are inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Limitations of use: Reserve tapentadol for use in patients for whom alternative treatment options (eg, nonopioid analgesics, opioid combination products) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Tapentadol ER is not indicated as an as-needed analgesic.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7083925\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Tapentadol may be confused with traMADol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878284\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immediate release:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (24%), drowsiness (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (30%), vomiting (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (3%), insomnia (2%), abnormal dreams (1%), anxiety (1%), confusion (1%), lethargy (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (3% to 5%), hyperhidrosis (3%), skin rash (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (8%), xerostomia (4%), decreased appetite (2%), dyspepsia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (1%), tremor (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (1%), upper respiratory tract infection (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal distress, abnormality in thinking, agitation, angioedema, ataxia, cough, decreased blood pressure, decreased heart rate, delayed gastric emptying, diarrhea, disorientation, drug withdrawal, dysarthria, dyspnea, edema, euphoria, feeling of heaviness, flatulence, hallucination, headache, hypersensitivity, hypoesthesia, hypogonadism (Brennan, 2013; Debono, 2011), impaired consciousness, increased gamma-glutamyl transferase, increased heart rate, increased serum ALT, increased serum AST, intoxicated feeling, irritability, lack of concentration, memory impairment, muscle spasm, nervousness, oxygen desaturation, palpitations, paresthesia, pollakiuria, presyncope, respiratory depression, restlessness, sedation, seizure, syncope, urinary hesitancy, urticaria, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extended release:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (17% to 18%), headache (10% to 15%), drowsiness (12% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (21% to 27%), constipation (13% to 17%), vomiting (8% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (9%), anxiety (2% to 5%), insomnia (4%), irritability (2%), lethargy (2%), abnormal dreams (1% to 2%), vertigo (1% to 2%), chills (1%), depression (1%), hypoesthesia (1%), lack of concentration (1%), nervousness (1%), sedation (1%), withdrawal syndrome (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (1% to 8%), hyperhidrosis (3% to 5%), skin rash (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (7%), xerostomia (7%), decreased appetite (2% to 6%), dyspepsia (1% to 3%), abdominal distress (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Erectile dysfunction (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (1% to 3%), weakness (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormality in thinking, agitation, altered mental status, anaphylaxis, angioedema, ataxia, confusion, decreased blood pressure, decreased heart rate, delayed gastric emptying, disorientation, drug dependence, dysarthria, equilibrium disturbance, euphoria, feeling abnormal, hallucination, hypersensitivity, hypogonadism (Brennan, 2013; Debono, 2011), illusion, impaired consciousness, increased heart rate, intoxicated feeling, left bundle branch block, memory impairment, nightmares, palpitations, panic attack, paresthesia, pollakiuria, presyncope, respiratory depression, sexual difficulty, suicidal ideation, syncope, urinary hesitancy, urticaria, visual disturbance, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878279\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis, angioedema) to tapentadol or any component of the formulation; significant respiratory depression; acute or severe asthma or hypercapnia in unmonitored settings or in absence of resuscitative equipment; GI obstruction, including paralytic ileus (known or suspected); use with or within 14 days of MAO inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to opioids; acute respiratory depression, cor pulmonale; obstructive airway; known or suspected gastrointestinal obstruction or any disease/condition that affects bowel transit (eg, ileus of any type, strictures); suspected surgical abdomen (eg, acute appendicitis, pancreatitis); severe renal impairment (CrCl &lt;30 mL/minute); severe hepatic impairment (Child-Pugh class C); mild, intermittent, or short-duration pain that can be managed with alternative pain medication; management of perioperative pain (extended-release tablets); acute alcoholism, delirium tremens, and seizure disorders; severe CNS depression, increased cerebrospinal or intracranial pressure or head injury; pregnancy; breast-feeding; use during labor/delivery</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878280\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: <b>[US Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely for respiratory depression, especially during initiation or dose escalation. Swallow ER tablets whole; crushing, chewing, or dissolving can cause rapid release and a potentially fatal dose.</b> Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with concomitant use of tapentadol and serotonergic agents (eg, SSRIs, SNRIs, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MAO inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biliary tract impairment: Use caution in patients with biliary tract dysfunction or acute pancreatitis; opioids may cause spasm of the sphincter of Oddi.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression/coma: Avoid use in patients with impaired consciousness or coma as these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delirium tremens: Use with caution in patients with delirium tremens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Serum concentrations are increased in hepatic impairment; use with caution in patients with moderate hepatic impairment (dosage adjustment required). Not recommended for use in severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mental health conditions: Use opioids with caution for chronic pain in patients with mental health conditions (eg, depression, anxiety disorders, post-traumatic stress disorder) due to increased risk for opioid use disorder and overdose; more frequent monitoring is recommended (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Use with caution in patients who are morbidly obese.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Use with caution in patients with toxic psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with mild to moderate renal impairment. Not recommended for use in severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale, and patients having a substantially decreased respiratory reserve, hypoxia, hypercarbia, or preexisting respiratory depression, particularly when initiating and titrating therapy;; critical respiratory depression may occur, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Use caution in patients with a history of seizures or conditions predisposing patients to seizures; may cause or exacerbate preexisting seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep-disordered breathing: Use opioids with caution for chronic pain and titrate dosage cautiously in patients with risk factors for sleep-disordered breathing, including HF and obesity. Avoid opioids in patients with moderate to severe sleep-disordered breathing (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzodiazepines or other CNS depressants: <b>[US Boxed Warning]: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of tapentadol and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosage and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Extended release: <b>[US Boxed Warning]: Patients should not consume alcoholic beverages or medication containing ethanol while taking tapentadol ER; ethanol may increase tapentadol plasma levels resulting in a potentially fatal overdose.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages. Consider the use of nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use opioids with caution in the elderly; consider decreasing initial dose. Use opioids for chronic pain with caution in this age group; monitor closely due to an increased potential for risks, including certain risks such as falls/fracture, cognitive impairment, and constipation. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increasing the risk for respiratory depression or overdose (Dowell [CDC 2016]). Consider the use of nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Neonatal withdrawal syndrome: <b>[US Boxed Warning]: Prolonged use of opioids during pregnancy can cause neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</b> Signs and symptoms include irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. Onset, duration, and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended release tablets: Therapy should only be prescribed by healthcare professionals familiar with the use of potent opioids for chronic pain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral solution: In order to avoid dosing errors, include the dose in mL and mg when writing prescriptions. Instruct patients to always use the enclosed calibrated oral syringe to ensure the dose is measured and administered accurately.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion: <b>[US Boxed Warning]: Tapentadol exposes patients and other users to the risks of addiction, abuse, and misuse, potentially leading to overdose and death. Assess each patient&rsquo;s risk prior to prescribing; monitor all patients regularly for development of these behaviors or conditions.</b> Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Other factors associated with increased risk for misuse include younger age, concomitant depression (major), and psychotropic medication use. Consider offering naloxone prescriptions in patients with factors associated with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (&ge;50 morphine milligram equivalents/day orally), and concomitant benzodiazepine use (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Accidental exposure: Extended release tablets: <b>[US Boxed Warning]: Accidental ingestion of even one dose, especially in children, can result in a fatal overdose of tapentadol.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Chronic pain (outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder) in outpatient setting in adults: Opioids should <b>not</b> be used as first-line therapy for chronic pain management (pain &gt;3-month duration or beyond time of normal tissue healing) due to limited short-term benefits, undetermined long-term benefits, and association with serious risks (eg, overdose, MI, auto accidents, risk of developing opioid use disorder). Preferred management includes nonpharmacologic therapy and nonopioid therapy (eg, NSAIDs, acetaminophen, certain anticonvulsants and antidepressants). If opioid therapy is initiated, it should be combined with nonpharmacologic and nonopioid therapy, as appropriate. Prior to initiation, known risks of opioid therapy should be discussed and realistic treatment goals for pain/function should be established, including consideration for discontinuation if benefits do not outweigh risks. Therapy should be continued only if clinically meaningful improvement in pain/function outweighs risks. Therapy should be initiated at the lowest effective dosage using immediate-release opioids (instead of extended-release/long-acting opioids). Risk associated with use increases with higher opioid dosages. Risks and benefits should be re-evaluated when increasing dosage to &ge;50 morphine milligram equivalents (MME)/day orally; dosages &ge;90 MME/day orally should be avoided unless carefully justified (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Opioids decrease bowel motility; monitor for decrease bowel motility in postop patients receiving opioids. Use with caution in the perioperative setting; individualize treatment when transitioning from parenteral to oral analgesics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Concurrent use of mixed agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol) or partial agonist (eg, buprenorphine) analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Taper dose gradually when discontinuing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300104\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C9 (minor), CYP2D6 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878927\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9511&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the CNS depressant effect of Tapentadol. Alcohol (Ethyl) may increase the serum concentration of Tapentadol. Specifically, alcohol may increase the maximum serum concentrations when used with extended-release tapentadol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alvimopan: Opioid Analgesics may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May enhance the analgesic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May diminish the analgesic effect of Tapentadol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: Tapentadol may enhance the CNS depressant effect of CNS Depressants.  Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Opioid Analgesics may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diuretics: Opioid Analgesics may enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Opioid Analgesics may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Opioid Analgesics may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: Tapentadol may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the additive effects of norepinephrine may lead to adverse cardiovascular effects. Tapentadol may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: May diminish the therapeutic effect of Opioid Analgesics. Management: Avoid the concomitant use of nalmefene and opioid analgesics. Discontinue nalmefene 1 week prior to any anticipated use of opioid analgesics. If combined, larger doses of opioid analgesics will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naltrexone: May diminish the therapeutic effect of Opioid Analgesics. Management: Seek therapeutic alternatives to opioids.  See full drug interaction monograph for detailed recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Analgesics. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: Opioid Analgesics may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Opioid Analgesics may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Opioid Analgesics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: May enhance the bradycardic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878303\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethanol: Concomitant use with alcohol can increase the bioavailability of extended release tablets. Management: Avoid use of alcohol during therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Food: When administered after a high fat/calorie meal, the AUC and C<sub>max</sub> increased by 25% and 16%, respectively. Management: May administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878274\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878275\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[U.S. Boxed Warning]: Prolonged maternal use of opioids during pregnancy can cause neonatal withdrawal syndrome in the newborn which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If prolonged opioid therapy is required in a pregnant woman, ensure treatment is available and warn patient of risk to the neonate.</b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse events were observed in some animal reproduction studies. Opioids cross the placenta. Maternal use of opioids may be associated with birth defects, poor fetal growth, stillbirth, and preterm delivery (CDC [Dowell 2016]). If chronic opioid exposure occurs in pregnancy, adverse events in the newborn (including withdrawal) may occur (Chou 2009). Symptoms of neonatal abstinence syndrome (NAS) following opioid exposure may be autonomic (eg, fever, temperature instability), gastrointestinal (eg, diarrhea, vomiting, poor feeding/weight gain), or neurologic (eg, high-pitched crying, hyperactivity, increased muscle tone, increased wakefulness/abnormal sleep pattern, irritability, sneezing, seizure, tremor, yawning) (Dow 2012; Hudak 2012). Mothers who are physically dependent on opioids may give birth to Infants who are also physically dependent. Opioids may cause respiratory depression and psycho-physiologic effects in the neonate; newborns of mothers receiving opioids during labor should be monitored.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Agents other than tapentadol are commonly used to treat maternal pain during labor and immediately postpartum (ACOG 177 2017) as well as chronic noncancer pain in pregnant women or those who may become pregnant (CDC [Dowell 2016]; Chou 2009; Kahan 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878278\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Although limited information is available, data suggests tapentadol may be present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Current guidelines note that nonopioid analgesics are preferred for postpartum pain in breastfeeding women (Montgomery 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When opioids are needed in breastfeeding women, the lowest effective dose for the shortest duration of time should be used to limit adverse events in the mother and breastfeeding infant. In general, a single occasional dose of an opioid analgesic may be compatible with breastfeeding (WHO 2002). Breastfeeding women using opioids for postpartum pain or for the treatment of chronic maternal pain should monitor their infants for drowsiness, sedation, feeding difficulties, or limpness (ACOG 177 2017; Montgomery 2012; Sachs 2013). Withdrawal symptoms may occur when maternal use is discontinued or breastfeeding is stopped. Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15040860\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">Respiratory and cardiovascular status, blood pressure, heart rate; signs of misuse, abuse, or addiction; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alternate recommendations: Chronic pain (long-term therapy outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder): Evaluate benefits/risks of opioid therapy within 1 to 4 weeks of treatment initiation and with dose increases. Re-evaluate benefits/risks every 3 months during therapy or more frequently in patients at increased risk of overdose or opioid use disorder. Urine drug testing is recommended prior to initiation and re-checking should be considered at least yearly (includes controlled prescription medications and illicit drugs of abuse). State prescription drug monitoring program (PDMP) data should be reviewed by clinicians prior to initiation and periodically during therapy (frequency ranging from every prescription to every 3 months) (Dowell [CDC 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878306\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to &mu;-opiate receptors in the CNS causing inhibition of ascending pain pathways, altering the perception of and response to pain; also inhibits the reuptake of norepinephrine, which also modifies the ascending pain pathway</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7878308\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: IV: 442-638 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensive metabolism, including first pass metabolism; metabolized primarily via phase 2 glucuronidation to glucuronides (major metabolite: tapentadol-O-glucuronide); minimal phase 1 oxidative metabolism; also metabolized to a lesser degree by CYP2C9, CYP2C19, and CYP2D6; all metabolites pharmacologically inactive</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: ~32%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Immediate release: ~4 hours; Long acting formulations: ~5-6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Immediate release: 1.25 hours; Long acting formulations: 3-6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (99%: 70% conjugated metabolites; 3% unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321931\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 12-hour</b> (Nucynta ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $448.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $830.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $1,070.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $1,359.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (60): $1,700.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Nucynta Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $694.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $811.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $1,081.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12992810\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cynta (BD);</li>\n      <li>Dol-Proxyvon (IN);</li>\n      <li>Lopenta (BD);</li>\n      <li>Nucynta SR (KR);</li>\n      <li>Paincure (BD);</li>\n      <li>Palexia (AT, BG, CH, CR, CZ, DK, DO, EE, ES, FI, FR, GB, GT, HN, HR, IE, IL, LT, LU, LV, MT, NI, NL, NO, PA, PL, PT, SI, SK, SV, TR);</li>\n      <li>Palexia Depot (DK, FI, NO, SE);</li>\n      <li>Palexia IR (AU);</li>\n      <li>Palexia PR (CY, TR);</li>\n      <li>Palexia Retard (AT, BG, CR, DE, DO, EE, ES, GT, HN, HR, LT, LV, MT, NI, NL, PA, PL, PT, RO, SK, SV);</li>\n      <li>Palexia SR (GB, IL, SG);</li>\n      <li>Palexias (HU);</li>\n      <li>Tapcynta (IN);</li>\n      <li>Tapenta (BD, JP);</li>\n      <li>Vorth-TP (IN);</li>\n      <li>Yantil (ES, HU, NL);</li>\n      <li>Yantil Retard (ES, NL);</li>\n      <li>{alexia SR (SI)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins&mdash;Obstetrics. Practice bulletin no. 177: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2017;129(4):e73-e89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/28333819/pubmed\" target=\"_blank\" id=\"28333819\">28333819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3)(suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/23414717/pubmed\" target=\"_blank\" id=\"23414717\">23414717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study [published correction appears in <i>Expert Opin Pharmacother</i>. 2010;11(16):2773]. <i>Expert Opin Pharmacother</i>. 2010;11(11):1787-1804.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/20578811/pubmed\" target=\"_blank\" id=\"20578811\">20578811</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chou R, Fanciullo GJ, Fine PG, et al, &quot;Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain,&quot;<i> J Pain</i>, 2009, 10(2):113-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/19187889/pubmed\" target=\"_blank\" id=\"19187889\">19187889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Debono M, Chan S, Rolfe C, Jones TH. Tramadol-induced adrenal insufficiency. <i>Eur J Clin Pharmacol</i>. 2011;67(8):865-867.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/21243342/pubmed\" target=\"_blank\" id=\"21243342\">21243342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dow K, Ordean A, Murphy-Oikonen J, et al, &quot;Neonatal Abstinence Syndrome Clinical Practice Guidelines for Ontario,&quot; <i>J Popul Ther Clin Pharmacol</i>, 2012, 19(3):e488-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/23241498/pubmed\" target=\"_blank\" id=\"23241498\">23241498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain&mdash;United States, 2016. <i>MMWR Recomm Rep</i>. 2016;65(1):1-49. doi: 10.15585/mmwr.rr6501e1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/26987082/pubmed\" target=\"_blank\" id=\"26987082\">26987082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hartrick C, Van Hove I, Stegmann JU, et al, &ldquo;Efficacy and Tolerability of Tapentadol Immediate Release and Oxycodone HCl Immediate Release in Patients Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease: A 10-Day, Phase III, Randomized, Double-Blind, Active- and Placebo-Controlled Study,&rdquo; <i>Clin Ther,</i> 2009, 31(2):260-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/19302899/pubmed\" target=\"_blank\" id=\"19302899\">19302899</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hudak ML, Tan RC, Committee On Drugs, et al, &quot;Neonatal Drug Withdrawal,&quot; <i>Pediatrics</i>, 2012, 129(2):e540-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/22291123/pubmed\" target=\"_blank\" id=\"22291123\">22291123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A; National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. <i>Can Fam Physician.</i> 2011;57(11):1269-1276.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/22084456/pubmed\" target=\"_blank\" id=\"22084456\">22084456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinert R, Lange C, Steup A, et al, &ldquo;Single Dose Analgesic Efficacy of Tapentadol in Postsurgical Dental Pain: The Results of a Randomized, Double-Blind, Placebo-Controlled Study,&rdquo; <i>Anesth Analg</i>, 2008, 107(6):2048-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/19020157/pubmed\" target=\"_blank\" id=\"19020157\">19020157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW; Academy Of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2012. <i>Breastfeed Med</i>. 2012;7(6):547-553.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nucynta ER (tapentadol) [prescribing information]. Newark, CA: Depomed, Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nucynta ER (tapentadol) [Canadian product monograph]. Dublin, Ireland: Endo Ventures Ltd; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nucynta IR (tapentadol) [prescribing information]. Newark, CA: Depomed, Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nucynta IR (tapentadol) [Canadian product monograph]. Dublin, Ireland: Endo Ventures Ltd; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. <i>Diabetes Care</i>. 2017;40(1):136-154. doi: 10.2337/dc16-2042.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/27999003/pubmed\" target=\"_blank\" id=\"27999003\">27999003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/23979084/pubmed\" target=\"_blank\" id=\"23979084\">23979084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwartz S, Etropolski M, Shapiro DY, et al, &quot;Safety and Efficacy of Tapentadol ER in Patients With Painful Diabetic Peripheral Neuropathy: Results of a Randomized-Withdrawal, Placebo-Controlled Trial,&quot; <i>Curr Med Res Opin</i>, 2011, 27(1):151-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/21162697/pubmed\" target=\"_blank\" id=\"21162697\">21162697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wild JE, Grond S, Kuperwasser B, et al, &quot;Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain,&quot; <i>Pain Pract</i>, 2010, 10(5):416-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tapentadol-drug-information/abstract-text/20602712/pubmed\" target=\"_blank\" id=\"20602712\">20602712</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9511 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50847616\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F13210109\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7878273\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F12785498\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F7083927\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7878389\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F7878390\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F7878324\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F7878325\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F7878394\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F7083931\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F12809985\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F7878271\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874994\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7878392\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F7083929\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7083925\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F7878284\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F7878279\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F7878280\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300104\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F7878927\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F7878303\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F7878274\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7878275\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F7878278\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F15040860\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F7878306\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F7878308\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321931\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12992810\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9511|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tapentadol-patient-drug-information\" class=\"drug drug_patient\">Tapentadol: Patient drug information \t</a></li></ul></div></div>","javascript":null}